S
Shi‐Ming Tu
High Impact
Professor
faculty
Internal Medicine, College of Medicine
36 h-index
134 pubs
5,059 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Shi-Ming Tu, a Professor in Internal Medicine at the University of Arkansas for Medical Sciences, focuses on the study of cancer, particularly prostatic neoplasms and germ cell tumors. His research investigates various treatment modalities, including antineoplastic combined chemotherapy protocols and the use of specific agents like Abiraterone acetate. Tu's work also explores the underlying biological theories of cancer, such as the stem cell theory, and its implications for tumor heterogeneity, plasticity, and dormancy.
His recent publications address critical aspects of cancer management, from optimizing the diagnosis and treatment of ductal prostate cancer to understanding very late recurrences in germ cell tumors of the testis. Tu also examines the development of somatic-type malignancies in testicular germ cell tumors. His scholarship is reflected in a high-impact researcher designation, with an h-index of 36, 134 total publications, and over 5,000 citations. He leads a research group and collaborates with researchers at his institution and elsewhere, including Sunny Singh and Andrew Johns.
Metrics
- h-index: 36
- Publications: 134
- Citations: 5,059
Selected Publications
-
Real-world effects of sodium-glucose cotransporter 2 inhibitor use on renal cell carcinoma. (2026)
-
Real-world effectiveness and safety of enfortumab vedotin plus pembrolizumab versus gemcitabine-platinum chemotherapy in first-line treatment of advanced urothelial carcinoma: A propensity-matched analysis from the TriNetX global network. (2026)
-
Real-world comparative outcomes of abiraterone vs enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC): A propensity-matched analysis from the TriNetX Global Health Research Network. (2026)
-
Stem Cell Origin of Cancer: Biological Principles and Clinical Strategies for Chemoprevention and Maintenance Therapy in Cancer Care (2025)
-
Start Time End Time Integration (STETI): Method for Including Recent Data to Analyze Trends in Kidney Cancer Survival (2025)
-
Bilateral germ cell tumor of the testis (TGCT): Implications for a stem cell versus genetic origin of cancers. (2025)
-
Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem Versus Genetic Origin of Cancers (2025)
-
Epithelioid trophoblastic tumor in male patients with germ cell tumor: A clinicopathologic analysis of five cases (2024)
-
Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer (2024)
-
Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care (2024)
-
Stem Cell Theory of Cancer: Clinical Implications for Cellular Metabolism and Anti-Cancer Metabolomics (2024)
-
Identification of a panel of microRNA biomarkers for the management of patients with refractory germ cell tumor of the testis. (2024)
-
Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care (2023)
-
Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy (2023)
-
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors (2023)
Grants & Funding
- S2200, A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2). SouthWest Oncology Group Principal Investigator
- 297214 A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) BicycleTx Limited Principal Investigator
- 297214 A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) BicycleTx Limited - Pass Through: Medpace Clinical Research Principal Investigator
Collaboration Network
Top Collaborators
Christopher J. Logothetis
15 shared publications
- Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer
- Conflict of Interest from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Supplementary Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Showing 5 of 15 shared publications
Sue-Hwa Lin
11 shared publications
- Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy?
- Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
Showing 5 of 11 shared publications
Ana M. Aparicio
10 shared publications
- Optimizing the diagnosis and management of ductal prostate cancer
- Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer
- Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Data from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
Showing 5 of 10 shared publications
Gary E. Gallick
10 shared publications
- Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Figure S1 from Cabozantinib Reverses Renal Cell Carcinoma–mediated Osteoblast Inhibition in Three-dimensional Coculture <i>In Vitro</i> and Reduces Bone Osteolysis <i>In Vivo</i>
Showing 5 of 10 shared publications
Louis L. Pisters
The University of Texas MD Anderson Cancer Center (US)
9 shared publications
- Optimizing the diagnosis and management of ductal prostate cancer
- Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity
- Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications
- Somatic-type Malignancies in Testicular Germ Cell Tumors: A Clinicopathologic Study of 63 Cases.
- Curing Cancer: Lessons from a Prototype
Showing 5 of 9 shared publications
Amado J. Zurita
9 shared publications
- Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer
- Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Data from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Data from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Showing 5 of 9 shared publications
Paul G. Corn
9 shared publications
- Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer
- Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Data from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Data from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Showing 5 of 9 shared publications
Patricia Troncoso
9 shared publications
- Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Data from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
- Data from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
Showing 5 of 9 shared publications
Miao Zhang
The University of Texas MD Anderson Cancer Center (US)
8 shared publications
- Optimizing the diagnosis and management of ductal prostate cancer
- Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity
- Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications
- Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem Versus Genetic Origin of Cancers
- Supplementary Data from A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
Showing 5 of 8 shared publications
John C. Araujo
The University of Texas MD Anderson Cancer Center (US)
6 shared publications
- Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer
- Data from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- Data from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- Supplementary Figure 1 from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
- Supplementary Figure 1 from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Showing 5 of 6 shared publications
Sacha Gnjatic
6 shared publications
- Conflict of Interest from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Supplementary Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Supplementary Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Showing 5 of 6 shared publications
Nasser K. Altorki
6 shared publications
- Conflict of Interest from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Supplementary Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Supplementary Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Showing 5 of 6 shared publications
Derek Ng Tang
6 shared publications
- Conflict of Interest from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Supplementary Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Supplementary Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Showing 5 of 6 shared publications
Vikas Kundra
6 shared publications
- Conflict of Interest from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Supplementary Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Supplementary Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Showing 5 of 6 shared publications
Gerd Ritter
6 shared publications
- Conflict of Interest from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Supplementary Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
- Supplementary Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Showing 5 of 6 shared publications
Similar Researchers
Based on overlapping research topics
Bruno Lopes Cancado Machado
University of Arkansas for Medical Sciences
Prostate Cancer Treatment and Research
Cancer Treatment and Pharmacology
Ann R. Henry
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
S. Chowdhury
Arkansas State University
Prostate Cancer Treatment and Research
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Sehrish Sardar
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Mesenchymal stem cell research
Amit K. Tiwari
University of Arkansas for Medical Sciences
Prostate Cancer Treatment and Research
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Timothy C. Chambers
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Mesenchymal stem cell research